TrialFuture oncology (London, England)2020

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma.

Danielle A Murphy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.